An open label randomized study to compare TATE versus TACE in patients with intermediate
stage Hepatocellular carcinoma who are not suitable for surgical resection or radiofrequency
ablation. The primary endpoint is Progression Free Survival. Secondary endpoints including CR
rate, Time to embolization failure, Duration of CR, OS, ORR, local control rate, time to
local recurrence and duration to local recurrence. The study treatment is to compare
Tirapazamine versus doxorubicin when combined with trans-arterial embolization. Study plans
to enroll 134 patients in 1:1 randomization for TATE or TACE. MRI will be used to assess
efficacy using a central radiological review for the final analysis.